| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-05-07 | RoACTEMRA®/ACTEMRA® outside Europe (tocilizumab) | rheumatoid arthritis | Roche (Switzerland) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | |
| 2012-05-04 | GFT505 | NAFLD (non-alcoholic fatty liver disease) NASH (non-alcoholic steatohepatitis) |
2 | Genfit (France) | Metabolic diseases - Liver diseases |
| 2012-05-03 | various antithrombotic therapies, including warfarin, acetylsalicylic acid, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules and Xarelto® (rivaroxaban). | non-valvular atrial fibrillation | observational study | Boehringer Ingelheim (Germany) | Cardiovascular diseases |
| 2012-05-03 | insulin-coated gold nanoparticles (insulin-passivated gold glyconanoparticles (MidaForm™ insulin) formulated into PharmFilm® for buccal delivery) | diabetes | 1 | Midatech (UK) | Metabolic diseases |
| 2012-05-02 | FluGEM® (mucosal influenza vaccine) | influenza infection |
preclinical | Mucosis (The Netherlands) | Infectious diseases |
| 2012-05-02 | V81444 (adenosine A2A receptor antagonist) | Parkinson’s Disease |
1 | Vernalis (UK) | Neurodegenerative diseases - CNS diseases |
| 2012-05-01 | RG7090 - RO4917523 | fragile X syndrome |
2 | Roche (Switzerland) | Genetic diseases - Rare diseases |
| 2012-04-27 | PraenaTest® test | Trisomy 21 | LifeCodexx (Germany) | Genetic diseases | |
| 2012-04-27 | Tysabri® (natalizumab) | multiple sclerosis | BiogenIdec (USA) Elan (Ireland) | Autoimmune diseases - Neurodegenerative diseases | |
| 2012-04-26 | levomilnacipran (1S, 2R-milnacipran) | major depressive disorder (MDD) |
3 | Pierre Fabre Medicament (France) Forrest Laboratories (USA) | CNS diseases - Mental diseases |
| 2012-04-26 | Vyvanse® (lisdexamfetamine dimesylate) | binge eating disorder |
2 | Shire (UK-USA) | CNS diseases - Mental diseases |
| 2012-04-26 | Copaxone® (glatiramer acetate injection) | relapsing-remitting multiple sclerosis (RRMS) | Teva Pharmaceutical Industries (Israel) | Autoimmune diseases - Neurodegenerative diseases | |
| 2012-04-26 | AMEP® (targeted biotherapy) | metastatic melanoma |
1-2 | BioAlliance Pharma (France) | Cancer - Oncology |
| 2012-04-25 | undisclosed Nanobody® | Alzheimer\'s disease |
1 | Boehringer Ingelheim (Germany) | Neurodegenerative diseases |
| 2012-04-25 | T-Track® CMV/EBV Test Systems | CMV (cytomegalovirus) infection |
Lophius Biosciences (Germany) | Infectious diseases - Renal diseases | |
| 2012-04-24 | Lemtrada® (alemtuzumab) | patients with relapsing-remitting multiple sclerosis (RRMS) who had relapsed while on prior therapy |
3 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2012-04-23 | Varisolve® (now Varithena® - polidocanol endovenous microfoam (PEM) | treatment for patients with saphenofemoral junction incompetence and symptomatic and/or visible varicose veins | 3 | BTG International (UK) | Cardiovascular diseases |
| 2012-04-23 | BioChaperone® PDGF-BB (Platelet Derived Growth factor) | diabetic foot ulcer | 2 | Adocia (France) | Metabolic diseases - Cardiovascular diseases |
| 2012-04-20 | insulin degludec (Degludec®) | type 1 and type 2 diabetes | 3 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2012-04-19 | siponimod (BAF312) | multiple sclerosis |
2b | Novartis (Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
